PAS
VNDA icon

Point72 Asia (Singapore)’s Vanda Pharmaceuticals VNDA Stock Holding History

Point72 Asia (Singapore)’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-63,403
Closed -$261K – 1517
2024
Q1 		$261K Buy
63,403
+58,231
+1,126% +$233K 0.07% 327
2023
Q4 		$21.8K Buy
+5,172
New +$20.9K 0.01% 446

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asia (Singapore)'s VNDA Position: Q2 2024 in Review

Point72 Asia (Singapore) sold out of Vanda Pharmaceuticals (VNDA) in Q2 2024, closing a stake of 63,403 shares — an estimated $261K sold.

Point72 Asia (Singapore) first reported a position in VNDA in Q4 2023 and held it in 2 quarters. The position peaked at $261K in Q1 2024. 148 funds tracked by Wall St. Rank hold VNDA as of Q2 2024.

  • Point72 Asia (Singapore) reported no remaining Vanda Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 63,403 Vanda Pharmaceuticals shares in Q2 2024, an estimated $261K.
  • Point72 Asia (Singapore) first reported a position in Vanda Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Point72 Asia (Singapore)'s Vanda Pharmaceuticals position peaked at $261K in Q1 2024.
  • 148 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2024, filed 14 Aug 2024.